J.P. Morgan Reiterates a Buy Rating on BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best stocks to buy with over 50% upside potential. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported its fiscal Q3 2025 results on October 27. Total revenues for the quarter were $776 million, reflecting a 4% growth compared to the prior year period. This growth was driven by strong revenue growth in VOXZOGO and PALYNZIQ, attributable to new patients initiating therapy across all regions.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) further reported that the year-to-date total revenues rose 11% year-over-year, supported by more than 20% revenue growth for PALYNZIQ and VOXZOGO.

Following the earnings release, J.P. Morgan analyst Jessica Fye reiterated a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on October 28, stating that she sees the company’s underlying business to be undervalued.

Despite current market skepticism, the company has potential and a strong base for growth, and holds a strategic market position with considerable capital for business development and a strong pipeline.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.